RSV pre-fusion F protein vaccine
Respiratory syncytial virus (RSV) vaccine
Brand names: Abrysvo, Arexvy
Adult dose
Dose: 0.5mL IM single dose (Abrysvo: ≥75y and 28–36w pregnant; Arexvy: ≥75y)
Route: IM (deltoid)
Frequency: single
Clinical pearls
- UK RSV programme (Sep 2024): adults ≥75y once; pregnant women 28–36w (passive infant protection)
- Co-administer with influenza/pneumococcal in different limb
Contraindications
- Severe hypersensitivity to vaccine components
Side effects
- Injection-site reactions
- Fatigue
- Headache
- Myalgia
- Guillain-Barré syndrome (rare signal — under surveillance)
Interactions
- Immunosuppressives reduce response
Reference: BNF; UKHSA Green Book Ch.27a; JCVI; https://bnf.nice.org.uk/drugs/respiratory-syncytial-virus-rsv-vaccine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- P/F Ratio (Horowitz Index) · Respiratory Assessment
- Murray Score for Acute Lung Injury (ALI/ARDS) · Respiratory Failure
- Fontan Circulation Risk Assessment · Congenital Heart Disease
- CURB-65 Score for Pneumonia · Infection
- 20/2/20 Risk Score for Smouldering Myeloma · Myeloma
- Multiple Myeloma Response Criteria (IMWG 2016) · Myeloma
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023